Genprex Secures Israeli Patent for REQORSA, Bolstering Global IP Portfolio
GNPX is trading near its 52-week low of $0.861 (5.6% above the low) on light trading volume (0.4× avg).
Summary
Genprex announced it has been granted a patent in Israel for its REQORSA gene therapy when used in combination with PD-1 antibodies for cancer treatment. This patent expands the company's intellectual property protection for REQORSA, which already holds combination patents in several major markets including the U.S. and Europe. For a micro-cap biotech like Genprex, strengthening its global IP portfolio for a key therapeutic candidate is a positive development, enhancing the long-term value and market potential of REQORSA. This news provides a positive counterpoint to recent corporate governance concerns regarding a proposed reverse stock split to maintain Nasdaq listing.
At the time of this announcement, GNPX was trading at $0.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $8M. The 52-week trading range was $0.86 to $55.00. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.